COMP <GO>
LUCD vs NYXH // FORWARD P/E MULTIPLE
Lucid Diagnostics Inc. (NASDAQ) VS. Nyxoah SA (NASDAQ) • 15-METRIC TALLY: LUCD 1
— NYXH 1
■ METRIC PARITY
LAST: $0.40 (-6.36%) • MKT CAP: $87.9M
forward-pe
—
LAST: $0.87 (-1.85%) • MKT CAP: $88.9M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LUCD VS. NYXH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LUCD | NYXH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.1 | 31.2 | +4.95 | LUCD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $87.9M | $88.9M | -$992.3K | NYXH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LUCD REV | NYXH REV | LUCD GROSS % | NYXH GROSS % | LUCD FCF | NYXH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$46.7M | — |
| FY 2024 | $4.3M | — | -50.0% | — | -$44.4M | — |
| FY 2023 | $2.4M | — | — | — | -$32.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LUCD // BETA —
NYXH // BETA —